Many patients with chronic idiopathic urticaria (CIU) experience symptoms despite high doses of H1-antihistamines, H2-antihistamines and/or leukotriene receptor antagonists. This placebo-controlled trial evaluated Omalizumab or safety ad add-on treatment of patients with CIU. It included 336 patients with CIU. They were randomly assigned to treatment group receiving six 300mg sc injections at 4 week intervals vs placebo. There was significant improvement of pruritis in the treatment group. The improvement continued through the 24 week treatment period but it was not sustained after discontinuation. Looks like omalizumab may be a new option for patients with this challenging condition.
Kaplan A, Ledford D, Ashby M, et al: Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013; 132:101-109.
You Might Also Enjoy...
Two large trials, DREAM and MENSA have found IL-5 therapy with mepolizumab to lower risk of exacerbation in patients with asthma with an eosinophilic phenotype.
Mold allergy is difficult to diagnose due to lack of standardized test material.
The current standard for diagnosis of Eosinophilic Esophagitis (EoE) is endoscopy with esophageal biopsy to determine the eosinophil count
Skin prick testing and serum IgE measurement are limited in their ability to predict positive or negative responses to oral peanut challenge.
Bronchial Thermoplasty (BT) has been shown to result in significant improvements in a number of asthma control measures in three randomized clinical trials in patients with moderate-to-severe, persistent asthma.
Recent studies have suggested that early regular exposure to allergenic foods may reduce the risk of food allergy.
